Breast cancer
|
MVs
|
CCL5, CCR6
|
metastasis, proliferation and cancer cell-induced angiogenesis
|
[5, 47]
|
Colorectal adenocarcinoma
|
MVs
|
CCR6, CX3CR1, CCL2
|
antiapoptotic effect on monocytes, AKT kinase activation,proliferation
|
[38, 49]
|
Gastric cancer
|
MVs
|
CCR6
|
tumor progression
|
[52]
|
Glioblastoma
|
EVs
|
CCR8, CCL18
|
proliferation and drug resistance
|
[56]
|
Haemophilia A
|
MVs
|
CXCL8, CXCL10, CCL2
|
immunological profile
|
[36]
|
Leukemia
|
Apoptotic blebs
|
CCR7, CCL19
|
immuno modulation
|
[50]
|
|
Exsomoes
|
CCL3, CCL4, CXCR4
|
cell survival and drug resistance
|
[74]
|
|
MVs
|
CXCR4, CCL12
|
cell survival
|
[68]
|
Lung carcinoma
|
MVs
|
CCR6, CX3CR1, CXCR4
|
metastasis, antiapoptotic effect on monocytes, AKT kinase activation
|
[38, 58]
|
|
Exsomoes
|
CCL2, CCL3, CCL4, CCL5, CCL20
|
antitumor immune response
|
[51]
|
Lymphoma
|
Exosomes
|
CCL2, CCL7
|
macrophage recruitment
|
[42]
|
Melanoma
|
Exosomes
|
CCL2, CCL3, CCL4, CCL5, CCL7, CCL20
|
macrophage recruitment, antitumor immune response
|
[42, 51]
|
|
MVs
|
CCL2
|
inhibi ttumor proliferation
|
[49]
|
Pancreatic adenocarcinoma
|
MVs
|
CCR6, CX3CR1, CCL2, CCL3, CCL4, CCL5, CXCL8
|
anti-apoptosis, AKT kinase activation, angiogenesis
|
[38, 39]
|
Prostate cancer
|
Oncosomes
|
CXCL12
|
oncogenic signaling
|
[23]
|